Epic Sciences

Press Releases


Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer

Medicare Draft Coverage Supports Clinical Utility of the Oncotype DX AR-V7 Nucleus Detect Test, Providing 25,000 Medicare Patients with Coverage Once LCD Is Finalized


Epic Sciences to Present Single Cell PSMA Analysis to Provide Insight into Tumor Heterogeneity and Links to Response with Anti-PSMA Therapy

Epic Sciences will be presenting data, in conjunction with Endocyte Inc., on single cell PSMA analysis at ASCO GU on February 8th, 2018.


Epic Sciences to Present at the 2nd Annual CTIC Capital Cross-Border China-US Healthcare Investment Summit.

Epic Sciences is one of six select companies chosen to present


Epic Sciences launches metastatic breast cancer circulating tumor cell panel.

Epic Sciences, Inc. announces the release of its breast cancer single-cell profiling panel. The Epic breast cancer panel is the most comprehensive breast cancer biomarker panel available for characterization of circulating tumor cells (CTCs) within a blood sample.


Epic Sciences launches single-cell microsatellite and chromosomal instability genomic analysis.

New capability identifies sub-clonal tumor microsatellite instability in metastatic cancers to understand patient selection for PD-1 inhibitors, PARP inhibitors and combination therapies.


Liquid biopsy test identifies androgen receptor protein expression in circulating tumor cells in women with metastatic breast cancer.

Epic Sciences along with researchers at the MD Anderson Cancer Center (MDA) have recently published their findings on androgen receptor (AR) protein expression in circulating tumor cells (CTCs) in patients with metastatic breast cancer in PLOS One. The publication, the most comprehensive today in characterizing the AR protein in CTCs of patients with breast cancer, identifies subclonal heterogeneity of AR protein.


Liquid biopsy tumor heterogeneity test predicts resistance to targeted therapy in metastatic prostate cancer patients.

A blood test measuring the diversity of individual circulating tumor cells correlates with differential survival on chemotherapy vs. targeted hormone therapy in metastatic prostate cancer and offers potential to guide treatment choices in multiple solid tumor cancers.